Evidence map›Paper›PMID 41825447›Full record

Trial reportStem cell reports2026

Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials.

Shane W English, Dean A Fergusson, Manoj Mathew Lalu, David W Courtman, Saad Khan, Mohamad Sobh, Irene Watpool, Josee Champagne, Samantha Hodgins, Bernard Thébaud and 7 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04400032 phase1 / phase2completednot on this map

Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19)

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2020 to 2021Enrolled15ConditionsAcute Respiratory Distress Syndrome, Covid19ArmsMesenchymal Stromal Cells
NCT04865107 phase2completednot on this map

Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2021 to 2022Enrolled22ConditionsCovid19, Acute Respiratory Distress SyndromeArmsUC-MSCs, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shane W EnglishClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Dean A FergussonClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Manoj Mathew LaluClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada; Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, Ottawa of Ottawa, Ottawa, ON, Canada.
David W CourtmanRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Saad KhanRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mohamad SobhClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Irene WatpoolClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Josee ChampagneClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Samantha HodginsRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Bernard ThébaudRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, Ottawa of Ottawa, Ottawa, ON, Canada.
Karim SolimanDepartment of Critical Care, Lakeridge Health, Oshawa, ON, Canada; Department of Critical Care, Queen's University, Kingston, ON, Canada.
Michaël ChasséDepartment of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Medicine, Université de Montréal, Montréal, QC, Canada.
Claudia C Dos SantosThe Keenan Research Centre for Biomedical Science of St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada; Institute of Medical Sciences and Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada.
Marius A MöbiusSaxonian Center for Feto/Neonatal Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany; Good Manufacturing Practice, Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Saxony, Germany.
Daniel FreundSaxonian Center for Feto/Neonatal Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany; Good Manufacturing Practice, Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Saxony, Germany.
Mario RüdigerSaxonian Center for Feto/Neonatal Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany.
Duncan J StewartDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada; Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, Ottawa of Ottawa, Ottawa, ON, Canada. Electronic address: djstewart@ohri.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability of immunomodulatory mesenchymal stromal cells (MSCs) to improve COVID-19-associated acute respiratory distress syndrome (ARDS) in clinical trials is uncertain. We assessed whether freshly cultured umbilical cord (UC)-derived MSCs improved outcomes in patients with severe COVID-19 ARDS. We enrolled 37 patients with severe COVID-19 ARDS: 15 in the phase 1 dose escalation and open label extension studies (NCT04400032), and 22 patients in the phase 2b randomized clinical trial (NCT04865107). Delivery of up to 270 × 10

Indexed as

COVID-19ImmunotherapyMesenchymal Stem Cell TransplantationRespiratory Distress SyndromeAdultAgedFemaleHumansLymphopeniaMaleMesenchymal Stem CellsMiddle AgedQuality of LifeSARS-CoV-2Treatment OutcomeUmbilical Cordacute respiratory distress syndromecell therapyCOVID-19immunomodulationlymphopeniamesenchymal stem cellsrandomized clinical trialSARS-CoV2

Identifiers

PMID41825447
PMCPMC13083786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.